What insurance policy changes affect CPT 81382?

There are 9 tracked policy changes affecting CPT 81382, including updates from Ambetter, Humana, Blue Cross NC. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 81382?

Payers that have issued tracked updates for CPT 81382 include: Ambetter, Humana, Blue Cross NC, BlueCross BlueShield of South Carolina, Aetna, Blue Cross Blue Shield of Rhode Island.

How do I get notified when CPT 81382 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 81382. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 81382?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

81382 Insurance Policy Changes

CPT 81382 is referenced in 9 tracked payer policy changes from Ambetter, Humana, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 81382 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Q3 2026 Provider Newsletter
Ambetter·Effective Oct 1, 2026
Ambetter of Alabama has implemented multiple policy updates effective October 1, 2026 and December 5, 2026, including prior authorization requirement changes for genetic testing and surgical procedures, plus new site-of-care selection requirements for musculoskeletal surgeries. The billing team must update systems to remove PA requirements for genetic testing codes, add PA requirements for specific sinus surgery codes, and implement new authorization workflows for orthopedic procedures starting in December.
Medium impact
Important Prior Authorization Updates
Ambetter·Effective Oct 1, 2026
Ambetter from Magnolia Health is updating prior authorization requirements effective October 1, 2026. Genetic testing (CPT 81378-81383, 86812-86813, 86817), home services (S9211, S9213, S9214), and transplant services (CPT 38208) no longer require prior authorization, while sinus surgery (CPT 31297) now requires prior authorization. These changes standardize PA requirements across markets and lines of business.
High impact
Molecular Diagnostic Assays and Breath Testing for Transplant Rejection - MEDICAID - FLORIDA (Revised)
Humana·Effective Apr 6, 2026
Humana Florida Medicaid has issued a comprehensive policy stating that molecular diagnostic assays and breath testing for transplant rejection are NOT covered. This includes gene expression profiling, donor-derived cell-free DNA tests, breath testing, HLA testing, and urine-based tests for allograft rejection.
High impact
Medical Policy Update February 11, 2026
Blue Cross NC·Effective Feb 11, 2026
Blue Cross NC updated multiple medical policies effective February 11, 2026, including changes to coverage criteria for STI testing, diabetes testing code additions, cervical cancer screening restrictions, and vaginitis testing limits. Several CPT codes were removed from covered services while new codes were added for specific conditions.
High impact
2025 October Medical Policy Updates
BlueCross BlueShield of South Carolina·Effective Oct 1, 2025
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan released October 2025 medical policy updates affecting 50+ policies. Key changes include: three NEW spine surgery policies (CAM 401, 400, 399), addition of 10+ new billing codes across cancer genomics and diagnostic testing (0590U, 0593U, 0597U, 0591U, 0578U, 0577U, 0592U, 0598U, 83884, 87626, 83630, 83993), expanded coverage for pathogen panel testing in immunocompromised members, and coverage expansions for fecal calprotectin and liver fibrosis testing. Most changes are effective 10/01/2025; majority are annual reviews with no policy intent changes but updated documentation/references.
High impact
2025 October Medical Policy Updates
BlueCross BlueShield of South Carolina·Effective Oct 1, 2025
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan released comprehensive October 2025 medical policy updates affecting 50+ policies, including three new spine surgery policies (CAM 401, CAM 400, CAM 399), addition of multiple new billing codes for genetic testing and diagnostic services effective 10/01/2025, and annual reviews with updated evidence/references for existing policies. Most changes involve CPT/HCPCS code additions and clarification updates with no change to coverage intent, but three new spine surgery policies require immediate review for coverage determination criteria.
Medium impact
Elivaldogene Autotemcel (Skysona) (CPB 1017, reviewed 2026-04-08)
Aetna·Effective Apr 8, 2026
Aetna has issued a new Clinical Policy Bulletin (CPB 1017, effective 2026-04-08) establishing coverage criteria for Skysona (elivaldogene autotemcel), a gene therapy for early active cerebral adrenoleukodystrophy (CALD) in boys ages 4-17. This is a specialized therapy requiring precertification, administration at designated Aetna Institutes GCIT Network facilities, and compliance with strict clinical and laboratory eligibility criteria. Billing teams must implement precertification requirements and ensure only qualifying patients are billed for this high-cost therapy.
Medium impact
Lovotibeglogene Autotemcel (Lyfgenia) (CPB 1053, reviewed 2025-12-31)
Aetna·Effective Dec 31, 2025
Aetna has issued a new clinical policy (CPB 1053, effective 2025-12-31) establishing coverage criteria for lovotibeglogene autotemcel (Lyfgenia), a gene therapy for sickle cell disease in patients aged 12+. The policy requires precertification through National Medical Excellence (NME) and mandates treatment at Aetna Institutes GCIT Network facilities. Coverage is limited to one lifetime dose for eligible patients meeting strict criteria including failed/contraindicated hydroxyurea therapy, no prior HSCT, and absence of multiple contraindicated conditions.
Medium impact
Medical policy updates
Blue Cross Blue Shield of Rhode Island·Effective May 1, 2025
BCBSRI has updated medical policies effective May 1 and June 1, 2025, affecting prior authorization requirements for durable medical equipment, expanding covered diagnosis codes for CA-125 testing and cardiovascular biomarker testing, and adding new requirements for human leukocyte antigen testing with mandatory modifier usage.

All billing codes J3590 99213 99214 99212 99202 99203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Q3 2026 Provider Newsletter

Important Prior Authorization Updates

Molecular Diagnostic Assays and Breath Testing for Transplant Rejection - MEDICAID - FLORIDA (Revised)

Medical Policy Update February 11, 2026

2025 October Medical Policy Updates

2025 October Medical Policy Updates

Elivaldogene Autotemcel (Skysona) (CPB 1017, reviewed 2026-04-08)

Lovotibeglogene Autotemcel (Lyfgenia) (CPB 1053, reviewed 2025-12-31)

Medical policy updates